Abstract: The present invention describes the role of HMGB1 in improving wound healing, in particular in a model of diabetes. Other evidences based on the effect of glycyrrhizin, the underexpression of HMGB1 in the skin and fibroblast of diabetic subjects, the accumulation of RAGE in the skin of diabetic mice and the chemoattractant properties of HMGB1 on normal and diabetic human cells demonstrate that HMGB1 can be advantageously utilized for preparing medicament specifically devoted to wound healing, in particular for diabetic subjects.

Abstract: An improved prosthetic graft for the bypass, replacement or repair of vessels and organs that are in contact with blood flow is disclosed. The prosthetic graft includes a porous prosthetic implant and adherent cells adhered to the outer surface of the implant. The adherent cells are transfected with at least one recombinant nucleic acid molecule encoding at least one protein that enhances patency of the graft. The prosthetic graft has a long-term patency and success rate that is superior to other previously described prosthetic grafts designed for such use. Also disclosed are methods of making and using such a graft.

Abstract: It is described a composition comprising an effective amount of the HMGBl protein or functional parts thereof, of HMGBl expressing vectors, for the treatment of tissue damage and/or to promote tissue repair and regeneration. It is further described a composition comprising an effective amount of an antagonist of the HMGBl protein for the treatment of adverse effects induced by necrotic tissue, such as recruitment and activation of mveloid cells, loss of the barrier function of endothelia, edema.